HomeCompareSNNSF vs JNJ

SNNSF vs JNJ: Dividend Comparison 2026

SNNSF yields 6680.03% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNNSF wins by $1048430609875574.63M in total portfolio value
10 years
SNNSF
SNNSF
● Live price
6680.03%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1048430609875574.63M
Annual income
$1,018,439,347,436,510,900,000.00
Full SNNSF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — SNNSF vs JNJ

📍 SNNSF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNNSFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNNSF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNNSF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNNSF
Annual income on $10K today (after 15% tax)
$567,802.27/yr
After 10yr DRIP, annual income (after tax)
$865,673,445,321,034,300,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, SNNSF beats the other by $865,673,445,321,034,300,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNNSF + JNJ for your $10,000?

SNNSF: 50%JNJ: 50%
100% JNJ50/50100% SNNSF
Portfolio after 10yr
$524215304937787.31M
Annual income
$509,219,673,718,255,450,000.00/yr
Blended yield
97.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

SNNSF
No analyst data
Altman Z
-1.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNNSF buys
0
JNJ buys
0
No recent congressional trades found for SNNSF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNNSFJNJ
Forward yield6680.03%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$1048430609875574.63M$30.3K
Annual income after 10y$1,018,439,347,436,510,900,000.00$4,689.40
Total dividends collected$1046418273320032.38M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SNNSF vs JNJ ($10,000, DRIP)

YearSNNSF PortfolioSNNSF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$678,703$668,002.67$10,592$272.30+$668.1KSNNSF
2$43,097,726$42,371,513.87$11,289$357.73+$43.09MSNNSF
3$2,560,691,905$2,514,577,338.13$12,123$472.89+$2560.68MSNNSF
4$142,371,694,857$139,631,754,518.83$13,141$629.86+$142371.68MSNNSF
5$7,407,827,649,192$7,255,489,935,695.20$14,408$846.81+$7407827.63MSNNSF
6$360,743,926,277,413$352,817,550,692,777.80$16,021$1,151.60+$360743926.26MSNNSF
7$16,443,371,422,893,148$16,057,375,421,776,314.00$18,122$1,588.22+$16443371422.88MSNNSF
8$701,636,178,252,099,200$684,041,770,829,603,500.00$20,930$2,228.20+$701636178252.08MSNNSF
9$28,029,217,232,769,806,000$27,278,466,522,040,058,000.00$24,792$3,191.91+$28029217232769.78MSNNSF
10$1,048,430,609,875,574,600,000$1,018,439,347,436,510,900,000.00$30,274$4,689.40+$1048430609875574.63MSNNSF

SNNSF vs JNJ: Complete Analysis 2026

SNNSFStock

SenSen Networks Limited develop and sell SenDISA platform-based products and services in Australia. It operates through Smart Cities, Gaming, and Retail segments. The company offers SenDISA software platform-based products and solutions for multiple applications comprising law enforcement, transport, gaming, retail, logistics, manufacturing, defence and security, autonomous vehicles, and transportation. Its software combines enterprise video, sensor data analytics, and edge-to-cloud servers that allows customers to make fast and accurate decisions and to automate business processes. The company also provides cities solutions like smart curb management, including fixed and mobile cameras and sensors; smart parking, such as parking guidance, payment and permit compliance, and automated access control, as well as occupancy, parking duration studies, and emerging data application solutions; infrastructure audits, including sign digitisation and audit and digitisation of city assets and audits, as well as road works signage and road infrastructure audits; road safety solutions, such as spot and average speed, distracted driver detection, u-turn enforcement, and bus lane enforcement solutions; and traffic and tolling solutions. In addition, it offers casino solutions, such as live table game data, real time intelligence, and side bet utilization solutions, as well as SenEYE-D to recognize who is playing and matching your database/system; and retail solutions. Further, the company provides smart surveillance solutions, such as multi-camera tracking, surveillance camera and network audit, accurate live occupancy, and fast and simple video export, as well as work, health, and safety solutions; and emerging solutions, including blind bots, games AI, tag and trace, and smart cub sensor. SenSen Networks Limited was incorporated in 2006 and is headquartered in Melbourne, Australia.

Full SNNSF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this SNNSF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNNSF vs SCHDSNNSF vs JEPISNNSF vs OSNNSF vs KOSNNSF vs MAINSNNSF vs ABBVSNNSF vs MRKSNNSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.